Optimizing CFTR modulator therapy management for cystic fibrosis through the ReX platform.

ABSTRACT:

Background

Cystic fibrosis (CF) is a chronic multi-systemic disease that requires a complex daily treatment regimen. Therefore, there is sub-optimal adherence to CF therapies, and it was shown to impact its clinical and economic burden. Cystic fibrosis transmembrane conductance regulator modulators (CFTRm) are high-cost medications that demonstrated significant benefit in clinical trials. The aim of this study was to evaluate the safety, usability, and efficacy of the ReX platform in medication management of CFTRm for the treatment of people with CF (pwCF).

Methods

ReX is a patient engagement platform consisting of a cloud-based management system and a cell-enabled handheld device intended to dispense oral medication into the patient's mouth, following a pre-programmed treat

SUBMITTER: Yaacoby-Bianu K 

PROVIDER: S-EPMC10766369 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature